✦ LIBER ✦

FP33-WE-04 Utilization and safety of natalizumab in patients with relapsing multiple sclerosis in the post-marketing setting

✍ Scribed by R. Hyde; C. Bozic; G. Belcher; T. Dong-Si; R. Kim; F. Lynn; M. Kooijmans-Coutinho; M.A. Panzara

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

FP33-WE-03 Effects of natalizumab treatm

✍ F. Munschauer; G. Giovannoni; P.W. O'Connor; J.T. Phillips; C.H. Polman; A. Pace 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Efficacy and tolerability of natalizumab

✍ F. Sangalli; L. Moiola; S. Bucello; P. Annovazzi; A. Rizzo; M. Radaelli; G. Vite 📂 Article 📅 2010 🏛 Springer Milan 🌐 English ⚖ 238 KB

PND9 THE COST-EFFECTIVENESS OF NATALIZUM

✍ K Meyer; E Chiao 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

The efficacy of natalizumab in patients

✍ Michael Hutchinson; Ludwig Kappos; Peter A. Calabresi; Christian Confavreux; Gav 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 170 KB

The efficacy of natalizumab in patients

✍ M. Hutchinson; L. Kappos; P. A. Calabresi; C. Confavreux; G. Giovannoni; S. L. G 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 356 KB

Natalizumab Use in Patients With Crohn's

✍ Pepio, Anthony M. ;Taylor, Lori ;Hogge, Gary S. ;Bloomgren, Gary ;Cristiano, Lyn 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 158 KB